Improved potency assay for human retinal pigment (RPE) cells and photoreceptor progenitor cells

By using fluorescent pH sensors or pH-sensitive fluorescent dyes combined with spectrophotometric detection, the problem of difficult to accurately measure the phagocytic activity of retinal pigment epithelial cells and photoreceptor progenitor cells in the prior art is solved, and RPE cells and photoreceptor progenitor cells are realized Efficient evaluation of function, suitable for the treatment of retinal diseases.

CN113930476BActive Publication Date: 2024-11-12ADVANCED CELL TECH INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202111336261.7
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Priority Date
2015-03-23
Filing Date
2016-03-23
Publication Date
2024-11-12
Estimated Expiration
2036-03-23

AI Technical Summary

Technical Problem

Existing methods are difficult to accurately distinguish and measure the phagocytic activity of retinal pigment epithelial cells (RPE cells) and photoreceptor progenitor cells, especially in in vitro experiments, where the fluorescence signal of FITC-labeled photoreceptor extracellular junctions is reduced at low pH environments and cannot Effectively represents the internalized quantity.

Method used

Fluorescent pH sensors or pH-sensitive fluorescent dyes, such as Rhodamine-based Red dyes, combined with spectrophotometric detection, use the differences in fluorescent signals in neutral and low pH environments to evaluate the phagocytic activity of cells.

Benefits of technology

Provides a more sensitive and accurate method to detect internalized phagocytosis of photoreceptor extraneous segments, which can distinguish the surface binding and internalized phagocytosis phases, improves the accuracy of the function evaluation of RPE cells and photoreceptor progenitor cells, and is suitable for the treatment of retina. Cell screening for diseases.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN113930476B_ABST
    Figure CN113930476B_ABST
Patent Text Reader

Abstract

The present disclosure provides a novel phagocytosis assay to test the function of RPE cells and photoreceptor progenitor cells, which uses pH-sensitive fluorescent markers.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] This application is a divisional application of CN201680029779.7.

[0002] Related Applications

[0003] This application claims the benefit of U.S. Provisional Application Serial No. 62 / 136,660, filed on March 23, 2015, entitled “Improved Potency Assays for Human Retinal Pigment Cells and Photoreceptor Progenitor Cells,” pursuant to 35 USC §119(e), the entire contents of which are incorporated herein by reference. Field of the Invention

[0004] The present invention relates to the use of a cell-based in vitro method for measuring phagocytosis of photoreceptor rod outer segments. background

[0005] The retinal pigment epithelium (RPE) is a pigmented cell layer outside the sensory neuroretina between the choroid below (the vascular layer behind the retina) and the retinal visual cells above (e.g., photoreceptors - rods and cones). The RPE is essential for the function and health of the photoreceptors and the retina. The RPE maintains photoreceptor function by recycling photopigments, delivering, metabolizing and storing vitamin A, engulfing photoreceptor rod outer segments, transporting iron and small molecules between the retina and choroid, maintaining Bruch's membrane and absorbing stray light to allow better image resolution. See, e.g., WO2009 / 051671; Engelmann and Valtink (2004) "RPE Cell Cultivation." Graefe's Archive for Clinical and Experimental Ophthalmology 242(1):65–67; IrinaKlimanskaya, Retinal Pigment Epithelium Derived From Embryonic Stem Cells, in Stem Cell Anthology 335–346 (Bruce Carlson ed., 2009).

[0006] RPE degeneration can lead to retinal detachment, retinal dysplasia or retinal atrophy, which is associated with many vision-altering diseases that lead to photoreceptor cell damage and blindness, such as choroideremia, diabetic retinopathy, macular degeneration (including age-related macular degeneration, AMD) and Stargardt's macular dystrophy (SMD), the two leading causes of blindness in adults and adolescents, respectively, worldwide. Although both are currently untreatable, there is evidence in preclinical models of macular degeneration that transplantation of hESC-derived RPE can rescue photoreceptor cells and prevent vision loss (Lund RD, Wang S, Klimanskaya I, et al. Human embryonic stem cell-derived cellsrescue visual function in dystrophic rats. Cloning and Stem Cells 2006; 8, 189-199; Lu B, Malcuit C, Wang S, et al. Long-term safety and function of RPE from human embryonic stem cells in preclinical models of macular degeneration. Stem Cells 2009; 21, 2125-2135).

[0007] Also contributing to some of the above diseases is the additional loss of post-mitotic neuronal cells. These retinal diseases include rod or cone dystrophy, retinal degeneration, retinitis pigmentosa (RP), diabetic retinopathy, macular degeneration, Leber congenital amaurosis and Stargardt disease. In most cases of retinal degeneration, cell loss is primarily in the outer nuclear layer (ONL) that includes the rod and cone photoreceptor cells.

[0008] Potential replacement sources of photoreceptor cells include stem cells. Early studies evaluated mouse cells, mouse stem cells, or heterogeneous retinal progenitor cell populations as possible sources of replacement cells for lost photoreceptor cells. These early studies described transplantation of photoreceptor progenitor cells from postnatal day 1 mouse retinas (Maclaren et al. Nature 444(9):203-207, 2006), in vitro generation of retinal progenitor cells from mouse embryonic stem cells (Ikeda et al. Proc. Natl. Acad. Sci. 102(32):11331-11336, 2005), generation of retinal progenitor cells from postnatal day 1 mouse retinas (Klassen et al. Invest. Ophthal. Vis. Sci. 45(11):4167-4175, 2004), implantation of bone marrow mesenchymal stem cells into the RCS rat model of retinal degeneration (Inoue et al. Exp. Eye 2004). Res.8(2):234-241,2007), generating retinal progenitor cells from the H1 human embryonic stem cell line, including ganglion cells, amacrine cells, photoreceptor cells in which 0.01% of the total cells express S-opsin or rhodopsin, bipolar cells and horizontal cells (Lamba et al. Proc. Natl. Acad. Sci. 10(34):12769-12774,2006), and inducing induced pluripotent stem cells (iPS) from human fibroblasts to generate retinal progenitor cells (Lamba et al. PLoS ONE 5(1):e8763.doi:10.1371 / journal.pone.0008763). None of these methods produce homogenous photoreceptor progenitor cells or photoreceptor cell populations for implantation. None of these methods produce homogenous photoreceptor progenitor cells or photoreceptor cell populations that exhibit in vivo rod or cone function (e.g., detectable by imparting improved visual acuity). The supply of donor-derived tissues (e.g., cadavers, fetal tissues, and living animals) from which photoreceptor cells and photoreceptor progenitor cells may be isolated is limited. Stem cells can proliferate and expand indefinitely in vitro, providing a potential source of non-donor derived cells for human treatment. Differentiating stem cells into homogeneous photoreceptor progenitor cells or photoreceptor cell populations can provide a large supply of non-donor derived cells for implantation and treatment of retinal diseases. Photoreceptor progenitor cells may have phagocytic activity.

[0009] In the U.S. Patent Application Serial No. 13 / 510,426 and PCTUS2012 / 65091 jointly owned and submitted on November 17, 2010, some subject matter is disclosed, including the method for preparing RPE cell, the composition of RPE cell, and the release assay (comprising phagocytosis assay) for RPE cell, such teaching is incorporated herein by reference. In the jointly owned PCTUS2014 / 029790, some subject matter is disclosed, including the method for manufacturing photoreceptor progenitor cells, and the composition of photoreceptor progenitor cells and the method for testing function (comprising phagocytosis assay), such teaching is incorporated herein by reference.

[0010] Overview

[0011] FITC-labeled photoreceptor outer segments (OS) (usually bovine or porcine) have been used to study phagocytosis of retinal pigment epithelium (RPE) in vitro. However, most quantitative methods used for phagocytosis assessment (FACS, fluorescence microplate reader) do not distinguish between surface-bound and internalized particles and therefore cannot specifically explain the mechanisms involved in the surface receptor binding and internalization phagocytosis stages. In addition, FITC fluorescence is sensitive to pH, and FITC fluorescence is significantly reduced at pH below 6, while the pH of lysosomes and phagosomes fused with lysosomes is below 5. Therefore, the fluorescence of FITC-labeled OS may not truly represent the amount of internalized OS.

[0012] Provided herein is a more sensitive and accurate assay for detecting the internalization engulfment of photoreceptor cell outer segments, which is an important measure of RPE cell and photoreceptor progenitor cell function, and is therefore an important release standard for the RPE cell and photoreceptor progenitor cell for the treatment of retinal diseases, retinal diseases such as cone or rod dystrophy, retinal degeneration, retinitis pigmentosa, choroideremia, diabetic retinopathy, macular degeneration (including age-related macular degeneration and myopic macular degeneration), Leber's congenital amaurosis and fundus flavimaculatus.See, for example, WO 2009 / 051671.

[0013] RPE cells as described herein work after transplantation. For this reason, RPE cells form a monolayer between the sensory nerve retina and the choroid in the experimenter (or patient) receiving the transplanted cells. RPE cells can also provide nutrition to adjacent photoreceptor cells, and process the photoreceptor outer segments that come off by engulfment.

[0014] The RPE cells suitable for transplantation can be selected based on many functions and / or phenotypic characteristics (including but not limited to phagocytic activity).For example, the RPE cells suitable for transplantation can be assessed according to its phagocytic activity and its proliferation effectiveness.For example, RPE cells can have a greater proliferation effectiveness than the cells from eye donors (for example, RPE cells are " young " than eye donors). This makes the RPE cells described herein have a longer useful life than the cells from eye donors.

[0015] A key parameter of RPE cell efficacy in clinical background is the quantitative measurement of the outer segment phagocytic activity of RPE cell pharmaceutical preparation.The engulfment of outer segment causes the cell fragments engulfed to accumulate in the low pH compartment of RPE cell.The invention provides the photoreceptor outer segment that has been combined with the detectable marker that can detect with spectrophotometry (i.e. covalent or non-covalent combination) to provide spectrophotometric signal, the detectable marker selectively has the first spectrophotometric signal when being present in neutral pH or physiological pH, i.e. 7-7.5 pH, and has the second spectrophotometric signal when being present in the low pH environment of intracellular compartment such as lysosome, phagosome, endosome etc. The difference between the first spectrophotometric signal and the second spectrophotometric signal can be the degree of fluorescence emission (intensity increased at low pH relative to neutral pH), the change of fluorescence emission wavelength between neutral and low pH, the change of fluorescence excitation wavelength between neutral and low pH value etc. in one or more.

[0016] In certain embodiments, detectable marker can be a fluorescent pH sensor, such as a fluorescent dye. Exemplary fluorescent dyes that can be used for the present invention can be a fluorescent dye moiety with an amino group (aliphatic or aromatic) as an indicator moiety that is sensitive to pH, wherein the amino group is an unprotonated amine under the pH of the culture medium, wherein RPE cells and outer segments are incubated together (i.e., neutral pH or physiological pH), and protonated under the pH of the intracellular compartment, and the outer segments are absorbed by cells such as RPE cells into the intracellular compartment by engulfment. When such dye adsorbs photons, when producing an excited electronic state, the electron transfer of the non-shared electron pair of amino is excited on the track vacated. This electron transfer called photoinduced electron transfer (PET) prevents the excited molecule from being exempted from emission conversion, so the fluorescence of the dye is quenched. The protonation of amino changes the properties and energy of the track of the electron pair, and terminates PET. As a result, the fluorescent reporter part responds to the change of pH. Because the protonation of amino eliminates quenching, the sensor based on PET becomes stronger fluorescence as pH decreases.

[0017] In certain embodiments, the fluorescent dye is a pH-sensitive dye based on rhodamine, as described in WO 2005 / 098437. These dyes have a benzene ring substituted ortho- to a xanthene moiety by -OH or -SH (or its deprotonated form). These dyes exhibit pH-dependence similar to that of amine PET indicators, but are designed to have pKa values ​​less than 6 based on the need for sensing of pH sensors that will target cellular compartments with a pH less than 6.

[0018] In another exemplary embodiment, the fluorescent marker is a fluorescent nanoparticle that is sensitive to pH. Fluorescent nanoparticles that are sensitive to pH mainly use polymers conjugated with small molecule pH-sensitive dyes (Srikun, D., J. Chem. Sci. 2011, 2, 1156; Benjaminsen, RV, ACS Nano 2011, 5, 5864; Albertazzi, L., J. Am. Chem. Soc. 2010, 132, 18158; Urano, Y., Nat. Med. 2009, 15, 104) or use pH-sensitive linkers to conjugate pH-insensitive dyes (Li, C, Adv. Fund. Mater. 2010, 20, 2222; Almutairi, J. Am. Chem. Soc. 2007, 130, 444). To further illustrate, WO 2013152059 describes a pH-tunable, highly activatable, multicolor fluorescent nanoplatform that can be tuned to be suitable for use in this assay.

[0019] Therefore, in one aspect, the present invention provides a method for assessing phagocytic activity, which comprises incubating cells with photoreceptor cell outer segments (POS) for a time and temperature sufficient to allow the cells to phagocytose the POS, wherein the POS fluoresces more strongly at an acidic pH than at a higher pH, and detecting the fluorescence intensity of the cells after incubation, wherein an increase in fluorescence compared to a control indicates phagocytosis of the POS by the cells.

[0020] In some embodiments, cells are incubated with POS at a temperature ranging from about room temperature to about 37° C. or about room temperature to about 40° C. In some embodiments, cells are incubated with POS at about room temperature, about physiological temperature, or about 37° C.

[0021] In some embodiments, the control is cells incubated with POS at less than room temperature. In some embodiments, the control is cells incubated with POS at 4°C.

[0022] Also provided herein is a method for assessing phagocytic activity in an adherent cell population, comprising incubating the adherent cell population with a photoreceptor outer segment (POS) for a time and temperature sufficient to allow cells in the cell population to phagocytose the POS, wherein the POS fluoresces more strongly at an acidic pH than at a higher pH, and detecting the fluorescence intensity of the cell population after incubation, wherein an increase in fluorescence compared to a control indicates phagocytosis of the POS by the cells.

[0023] In some embodiments, the adherent cell population is incubated with the POS at a temperature range of about 17-40° C., or about 25-40° C., or about 34-40° C., or at a temperature of about 37° C. In some embodiments, the control is a cell population incubated with the POS at a temperature of about 10-16° C. In some embodiments, the control is a cell population incubated with the POS at a temperature of about 12-15° C.

[0024] Also provided herein is a method for assessing phagocytic activity, comprising providing a photoreceptor cell outer segment (POS) labeled with a fluorescent marker, which, when internalized into a low pH compartment of a cell by phagocytosis, has an altered fluorescence signal relative to the fluorescence signal when the fluorescent marker is present extracellularly; incubating test cells with the labeled POS under conditions that allow phagocytosis of the labeled POS; and detecting the altered fluorescence (if any) in the test cells after incubation with the labeled POS, and thereby quantifying the phagocytic activity of the test cells.

[0025] In some embodiments, the changed fluorescent signal (when the label enters the low pH compartment by phagocytosis internalization) is an increase in the intensity of the fluorescent signal relative to when the fluorescent label is present outside the cell. In some embodiments, the changed fluorescent signal (when the label enters the low pH compartment by phagocytosis internalization) can be detected by flow cytometry. In some embodiments, the changed fluorescent signal will be distinguished by the labeled POS internalized by phagocytosis and the labeled POS that is bound to the surface of the test cell but not internalized. In some embodiments, the changed fluorescent signal detected in the test cell is compared with a control cell group incubated with the labeled POS to quantitatively test the phagocytic activity of the cell.

[0026] In some embodiments, the test cells are incubated with the labeled POS at about room temperature, about physiological temperature, about 37°C, about 15-40°C, or between room temperature and 37°C, or between room temperature and 40°C.

[0027] In some embodiments, the control cell population is incubated with the labeled POS at below room temperature (including about 4°C).

[0028] Also provided is a method for assessing phagocytic activity, comprising providing a photoreceptor cell outer segment (POS) labeled with a fluorescent marker, which, when internalized into a low pH compartment of a cell by phagocytosis, has an altered fluorescence signal relative to the fluorescence signal when the fluorescent marker is present extracellularly; incubating adherent test cells with the labeled POS under conditions that permit phagocytosis of the labeled POS; and detecting the altered fluorescence (if any) in the adherent test cells following incubation with the labeled POS, and thereby quantifying the phagocytic activity of the adherent test cells.

[0029] In some embodiments, the test cells are incubated with POS at a temperature range of about 17-40°C, or about 25-40°C, or about 34-40°C, or at a temperature of about 37°C. In some embodiments, the altered fluorescence signal detected in the adherent test cells is compared with a control cell population incubated with the labeled POS at a temperature that maintains cell viability but still induces low or no phagocytosis, optionally, such a temperature range can be from about 12-15°C, to quantify the phagocytic activity of the test cells. In some embodiments, the control cell population is incubated with POS at a temperature of about 10-16°C.

[0030] Also provided herein are labeled photoreceptor cell outer segments (POS) preparations for evaluating the phagocytic activity of a test cell population, wherein the POS is labeled with a fluorescent marker that, when internalized into a low pH compartment of a cell by phagocytosis, has an altered fluorescent signal relative to the fluorescent signal when the fluorescent marker is present extracellularly. In some embodiments, the altered fluorescent signal (when the marker is internalized into the low pH compartment by phagocytosis) is an increase in the intensity of the fluorescent signal relative to when the fluorescent marker is present extracellularly. In some embodiments, the altered fluorescent signal (when the marker is internalized into the low pH compartment by phagocytosis) can be detected by flow cytometry. In some embodiments, the fluorescent marker is In some embodiments, the POS is used Red and Red E.coli BioParticles marker.

[0031] Also provided herein is a method for measuring phagocytic activity in a cell population, comprising measuring test fluorescence in a test cell population contacted with a non-FITC fluorescently labeled photoreceptor cell outer segment (POS), and comparing the measured test fluorescence to a control fluorescence, wherein the non-FITC fluorescently labeled POS fluoresces at an acidic pH but does not fluoresce or fluoresces minimally at a higher pH.

[0032] In some embodiments, the test cell population is contacted with a non-FITC fluorescently labeled POS at a temperature range of about room temperature to about physiological temperature, including, for example, about 37°C (i.e., about room temperature to about 37°C) or about room temperature to about 40°C. In some embodiments, the test cell population is contacted with a non-FITC fluorescently labeled POS at a temperature of about 15-40°C or about physiological temperature (including, for example, about 37°C). In some embodiments, the control fluorescence is the fluorescence of a cell population contacted with a non-FITC fluorescently labeled POS at less than room temperature. In some embodiments, the control fluorescence is the fluorescence of a cell population contacted with a non-FITC fluorescently labeled POS at 4°C.

[0033] Also provided herein is a method for measuring phagocytic activity in an adherent cell population, comprising measuring test fluorescence in an adherent test cell population contacted with a non-FITC fluorescently labeled photoreceptor cell outer segment (POS), and comparing the measured test fluorescence to a control fluorescence, wherein the non-FITC fluorescently labeled POS fluoresces at an acidic pH but does not fluoresce or fluoresces minimally at a higher pH.

[0034] In some embodiments, the test cell population is contacted with a non-FITC fluorescently labeled POS at a temperature range of about 17-40°C, about 25-40°C, about 34-40°C, or at a temperature of about 37°C.

[0035] In some embodiments, the control fluorescence is the fluorescence of an adherent cell population contacted with a non-FITC fluorescently labeled POS at a temperature of about 12-15° C. In some embodiments, the control fluorescence is the fluorescence of an adherent cell population contacted with a non-FITC fluorescently labeled POS at a temperature of about 10-16° C.

[0036] The present invention also provides a method for measuring phagocytic activity, which comprises (1) measuring and using (2) measuring the fluorescence of a first aliquot of a cell population incubated at a temperature ranging from about room temperature to about physiological temperature, including, for example, about 37° C., or about room temperature to about 40° C., and (3) measuring the fluorescence of a fluorescently labeled photoreceptor outer segment (POS) labeled with a Red dye in a first aliquot of a cell population incubated at a temperature ranging from about room temperature to about physiological temperature, including, for example, about 37° C., or about room temperature to about 40° C. The control fluorescence of the fluorescently labeled POS labeled with Red dye in a second aliquot of the cell population incubated at below room temperature, wherein a test fluorescence stronger than the control fluorescence indicates phagocytic activity of the cell population.

[0037] Also provided herein is a method for measuring phagocytic activity, comprising (1) measuring and using (2) measuring the fluorescence of a first aliquot of an adherent cell population incubated with fluorescently labeled photoreceptor outer segments (POS) labeled with a Red dye, and (3) measuring the fluorescence of a first aliquot of an adherent cell population incubated with fluorescently labeled photoreceptor outer segments (POS) labeled with a Red dye, and (4) measuring the fluorescence of a second aliquot of an adherent cell population incubated with fluorescently labeled photoreceptor outer segments (POS) labeled with a Red dye. The control fluorescence in a second aliquot of the adherent cell population incubated with fluorescently labeled POS labeled with Red dye, wherein a test fluorescence stronger than the control fluorescence indicates phagocytic activity of the cell population.

[0038] In some embodiments, a first aliquot of the adherent cell population is incubated with the labeled POS at a temperature range of about 17-40° C., or about 25-40° C., or about 34-40° C., or about 37° C. In some embodiments, a second aliquot of the adherent cell population is incubated with the labeled POS at a temperature range of about 10-16° C. or 12-15° C.

[0039] Also provided herein is a method for measuring phagocytic activity, comprising (1) measuring Red-labeled photoreceptor outer segments (POS) or Red and Red E. coli BioParticles labeled photoreceptor outer segments (POS) in a first aliquot of a cell population incubated at a temperature ranging from about room temperature to about physiological temperature, including 37° C., or from about room temperature to about 40° C., and (2) measuring fluorescence in a first aliquot of a cell population compared to that obtained with only Red-labeled photoreceptor outer segments (POS) or Red and Control fluorescence of Red E. coli BioParticles labeled photoreceptor outer segments (POS) in a second aliquot of the cell population incubated at below room temperature, including 4°C, wherein a test fluorescence greater than the control fluorescence indicates phagocytic activity of the cell population.

[0040] Also provided herein is a method for measuring phagocytic activity, comprising (1) measuring Red-labeled photoreceptor outer segments (POS) or Red and coli BioParticles labeled photoreceptor outer segments (POS) in a first aliquot of an adherent cell population incubated at a temperature range of about 17-40°C, or about 25-40°C, or about 34-40°C, or at a temperature of about 37°C, and (2) measuring fluorescence in a first aliquot of an adherent cell population incubated at a temperature range of about 17-40°C, or about 25-40°C, or about 34-40°C, or about 37°C, and Red-labeled photoreceptor outer segments (POS) or Red and Control fluorescence in a second aliquot of an adherent cell population incubated with Red E. coli BioParticles labeled photoreceptor outer segments (POS) at a temperature range of about 10-16°C or about 12-15°C, wherein a test fluorescence stronger than the control fluorescence indicates phagocytic activity of the cell population.

[0041] Various embodiments are equally applicable to any and all of the above aspects. These are described below.

[0042] In some embodiments, the cells, cell populations, test cells, or test cell populations are incubated with the POS at about room temperature, at about physiological temperature, or at about 37° C., or at about room temperature to about 40° C., or at about room temperature to about 37° C., or at about 15-40° C. In some embodiments, the cells, cell populations, test cells, or test cell populations are incubated with the labeled POS at a temperature range of about 17-40° C., or about 25-40° C., or about 34-40° C., or at a temperature of about 37° C.

[0043] In some embodiments, the control cell, control cell population, control test cell, or control test cell population is incubated with the POS at a temperature below room temperature, a temperature range of about 10-16°C or about 12-15°C, or a temperature of about 4°C.

[0044] In some embodiments, cell, cell group, test cell or test cell group comprises retinal pigment epithelium (RPE) cell.In some embodiments, cell, cell group, test cell or test cell group comprises photoreceptor progenitor cell.In some embodiments, cell, cell group, test cell or test cell group is human cell.

[0045] In some embodiments, the cell, cell population, test cell, or test cell population is generated by in vitro differentiation of pluripotent stem cells.

[0046] In some embodiments, cells, cell populations, test cells, or test cell populations are stored frozen and thawed prior to use.

[0047] In some embodiments, the cell, cell population, test cell, or test cell population is provided as a confluent monolayer.

[0048] In some embodiments, the cell, cell population, test cell, or test cell population is enzymatically digested prior to use.

[0049] In some embodiments, the cells, cell populations, test cells, or test cell populations are provided as an adherent cell population.

[0050] In some embodiments, the POS is a disrupted POS. In some embodiments, the POS is an ultrasonicated POS.

[0051] In some embodiments, the fluorescent label is Therefore, in some embodiments, the POS Red dye labeling. In some embodiments, POS is Red and RedE.coli BioParticles are labeled. In some embodiments, cells are Red marked POS and Red E.coli BioParticles incubation.

[0052] In some embodiments, fluorescence is detected by flow cytometry. In some embodiments, fluorescence is detected using a microplate reader.

[0053] In some embodiments, the cells are incubated with POS for about 15-30 hours, or 16-20 hours, or 20-28 hours.

[0054] In some embodiments, the cells are provided as a cell culture. In some embodiments, the cells are a confluent cell culture.

[0055] It should be understood that the test and control cells can be different aliquots of the same cell population.

[0056] On the other hand, present disclosure provides the cell mass of separation, it is characterized in that the phagocytic rate of its photoreceptor outer segment (POS) is higher than the phagocytic rate of the POS of equal number of primary cells by at least 50%.In some embodiments, cell mass is RPE cell mass.In some embodiments, cell mass is the RPE cell mass obtained by the in vitro differentiation of pluripotent stem cells, and primary cells are RPE cells from the adult eye of separation.In some embodiments, cell mass is photoreceptor progenitor cell.

[0057] These and various other aspects and embodiments are described in greater detail herein. BRIEF DESCRIPTION OF THE DRAWINGS

[0058] Figure 1A -C. FACS analysis of RPE phagocytosis. (A) FITC-labeled ROS. (B) Labeled ROS. Shown are curves for a control without added ROS, a control with added ROS and cells incubated at 4°C, and a test with added ROS and cells incubated at 37°C. (C) Labeled BioParticles (bacterial fragments). Shown are curves for a control group without added particles, a control group with added particles and cells incubated at 4°C, and a test with added particles and cells incubated at 37°C. It should be understood that POS and ROS are used interchangeably herein to refer to the outer segments of photoreceptor rod cells.

[0059] Figure 2A -B. FITC (A) and (B) pH dependence of the fluorescence of labeled ROS. Plotted are the fluorescence at neutral pH and acidic pH.

[0060] Figure 3A -F. FACS analysis of ARPE19 monolayer phagocytosis of fluorescently labeled ROS. When different concentrations of fluorescently labeled ROS were incubated with ARPE-19 in cell monolayer for 24 h, no dose-dependent phagocytic response was observed. (A) 6×10 6 ARPE-19 was incubated with ROS Red at 37°C. (B) 6 ARPE-19 was incubated with ROS Red at 37°C. (C) 6 Red-labeled ROS was incubated at 37°C in ARPE-19. (D) 6×10 6 Red-labeled ROS was incubated at 15°C in ARPE-19. (E) 3×10 6 Red-labeled ROS was incubated at 15°C in ARPE-19. (F) 1.5×10 6 Red labeled ROS incubated ARPE-19 at 15° C. In each graph, curves for cells not incubated with ROS and cells incubated with ROS are shown.

[0061] Figure 4A -F. FACS analysis of hESC-derived RPE cells phagocytosing fluorescently labeled ROS. When different concentrations of fluorescently labeled ROS were incubated with RPE in cell monolayers at 37°C for 24 h, no dose-dependent phagocytic response was observed. Pulse sonication of fluorescently labeled ROS during reconstitution increased phagocytosis by approximately 10%. (A) 3.75×10 6 (B) RPE cells incubated with ROS labeled with Red. (C) 5×10 6 (C) RPE cells incubated with ROS labeled with Red. (D) 7.5×10 6 RPE cells incubated with ROS labeled with Red. (D) 10×10 6 RPE cells incubated with ROS labeled with Red. (E) 10×10 6 (F) RPE cells incubated with ROS labeled with Red. (F) 13.5×10 6 RPE cells incubated with Red-labeled ROS.

[0062] Details

[0063] By exposure to Phagocytosis (efficacy assay) was assessed by quantitative fluorescence-activated cell sorting (FACS) analysis of RPE cultures of photoreceptor outer segments (POS) labeled with PD-L1 Red dye (Life Technologies, Molecular Probes).

[0064] You can use Phagocytosis is assessed by FACS-based assay of POS labeled with Αβ-DYNAMIC Red dye (Life Technologies, Molecular Probes). The dye and POS so labeled fluoresce when internalized into the reduced pH environment of intracellular phagosomes. POS can be labeled as described herein.

[0065] In some embodiments, the RPE cell culture is confluent. For example, confluent RPE can be cultured in a multi-well plate and can be used with Red dye-labeled POS is incubated, optionally incubated in the presence of a culture medium (Invitrogen) that is independent of CO2. Any time sufficient to engulf POS by RPE cells can be incubated. For example, 16-20 hours can be incubated. Measured at a temperature sufficient to engulf POS by RPE cells. In some embodiments, measured at about physiological temperature or about 37 ° C. In some embodiments, measured at room temperature. In some embodiments, incubate control (or negative control) plates at 4 ° C. Cells can be examined under a microscope, fluorescence can be measured using an ELISA instrument, and / or cells can be harvested after enzyme digestion (e.g., trypsin digestion) and analyzed by flow cytometry.

[0066] Exemplary, non-limiting assays are as follows:

[0067] The phagocytic ability of RPE prepared by pluripotent stem cells (such as but not limited to ES cells and iPS cells) as previously described is tested. The RPE of cryopreservation can be previously frozen and thawed before use. RPE cells are inoculated in the culture in the appropriate culture medium and cultured to converge and remain in the culture, and then test its phagocytic ability. The ability of POS labeled with Red dye, which fluoresces when internalized in the acidic environment of the phagosome of RPE cells. RPE cells are incubated with labeled POS at 37 ° C to allow engulfment, or incubated at 4 ° C as a negative control. The shift in the fluorescence intensity of cells incubated at 37 ° C can be detected by flow cytometry, indicating that the labeled POS has been engulfed. The statistical integration of the peaks produces the percentage of engulfment-positive cells for each batch of RPE cells and incubation temperature.

[0068] As will be appreciated by this disclosure, phagocytosis is detected by incubating RPE cells with labeled POS that fluoresces in the red spectrum in the acidic phagosomal environment. Cells incubated at 37°C or at 4°C (negative control) can show the percentage of phagocytosis-positive cells as detected by flow cytometry.

[0069] According to method provided herein, the RPE cell mass of gained can be characterized based on its phagocytic activity.Can determine phagocytic rate, and characterize RPE cell in this way.For example, the phagocytic rate that RPE cell can be characterized as POS is higher than the phagocytic rate of equal number photoreceptor cell outer segment (POS) of the RPE cell of the adult eye of separation by at least 50%, or higher than the phagocytic rate of equal number photoreceptor cell outer segment (POS) of the RPE cell of the adult eye of separation by at least 75%, 100%, 150% or 200%.Alternatively or additionally, the phagocytic rate that RPE cell can be characterized as photoreceptor cell outer segment (POS) is at least 20% of the POS total concentration after 24 hours, or is at least 25%, 30%, 25%, 40% or 50% of the POS total concentration after 24 hours.

[0070] Thus, using the methods described herein, a population of RPE cells has been obtained whose phagocytosis of photoreceptor outer segments (POS) is at least 50% higher, more preferably at least 75%, 100%, 150% or even 200% higher than the phagocytosis of an equal number of POS isolated from the eyes of adult RPE cells (i.e., adults aged 25-80 years, more preferably adults aged 50-80 years).

[0071] Using the methods described herein, RPE cell populations have been obtained whose phagocytosis of photoreceptor outer segments (POS) is at least 20% of the total POS concentration after 24 hours, more preferably at least 25%, 30%, 25%, 40% or even 50% of the total POS concentration after 24 hours.

[0072] Therefore, the present disclosure provides a method in one aspect, which includes detecting or measuring the fluorescence in the RPE cells (or RPE cell groups) contacted with the fluorescently labeled photoreceptor cell outer segment (POS) of non-FITC fluorescent labeling (considered as test fluorescence, or generally "test") and comparing the fluorescence detected or measured with a control (considered as control fluorescence or generally "control"). The test can be carried out at about room temperature, or at a temperature of about 15-40 ° C, or at a temperature of about physiological temperature (e.g., about 37 ° C). The control can be carried out at about 4 ° C. Therefore, the control fluorescence can be the fluorescence detected or measured after incubating RPE cells at 4 ° C with the POS of non-FITC fluorescent labeling. The POS of non-FITC fluorescent labeling is a POS labeled with a fluorophore that is not FITC. The non-FITC fluorescent labeling is a marker that fluoresces under the pH of an acidic pH, such as a phagosome, particularly a phagosome of an RPE cell, but it does not fluoresce or emits minimal fluorescence under a higher pH, such as a neutral pH (or an extracellular environment pH). The non-FITC fluorescent labeling can be used to distinguish surface markers from internalized markers. The example of such a fluorophore is Red dye (Life Technologies, Molecular Probes). A higher degree of phagocytosis in the assay is indicated by a stronger fluorescence compared to the control.

[0073] Therefore, in another aspect, the present disclosure provides a method comprising:

[0074] (1) Detection or measurement and use fluorescence in a first aliquot of RPE cells (or a population of RPE cells) contacted with (and incubated with) RPE cells (or a population of RPE cells) at 37°C (referred to as the test fluorescence, or generally "test"), and

[0075] (2) Detection or measurement and use fluorescence in a second aliquot of RPE cells (or a population of RPE cells) contacted with (and incubated with) RPE cells labeled with fluorescently labeled photoreceptor outer segments (POS) labeled with Red dye at 4°C (considered the control fluorescence, or often "control"), and

[0076] (3) optionally comparing, determining and / or quantifying the test and control fluorescence, wherein a test fluorescence that is greater than the control fluorescence is indicative of phagocytic activity of the RPE cell (or cell population).

[0077] It will be appreciated that the methods described herein can also be used to measure phagocytic activity in photoreceptor progenitor (or precursor) cells.

[0078] In certain embodiments, RPE and photoreceptor progenitor cells have phagocytic activity, such as phagocytosis of isolated Red photoreceptor outer segment, Red E. coli BioParticles, or both, and the methods provided herein measure one or more of these functions.

[0079] On the one hand, the disclosure provides a measure for determining the effectiveness of a pharmaceutical composition, the pharmaceutical composition comprising: a plurality of retinal pigment epithelial (RPE) cells or photoreceptor progenitor cells; and a pharmaceutically acceptable carrier. In one embodiment, the average melanin content of the plurality of RPE cells is less than 8pg / cell. The RPE cells or photoreceptor progenitor cells may be included in a suspension, a gel, a colloid, a matrix, a substrate, a support or a graft.

[0080] The pharmaceutically acceptable carrier may comprise a sterile solution having an osmotic pressure of about 290 mOsm / kg to about 320 mOsm / kg, or at about 300 mOsm / kg to 310 mOsm / kg or about 305 mOsm / kg. The pharmaceutically acceptable carrier may comprise a balanced salt solution. The balanced salt solution may comprise sodium chloride 7.14 mg, potassium chloride 0.38 mg, calcium chloride dihydrate 0.154 mg, magnesium chloride hexahydrate 0.2 mg, disodium hydrogen phosphate 0.42 mg, sodium bicarbonate 2.1 mg, dextrose 0.92 mg, glutathione disulfide (oxidized glutathione) 0.184 mg and hydrochloric acid and / or sodium hydroxide (pH adjusted to about 7.4) in each mL of water or consist of or consist essentially of.

[0081] The volume of the pharmaceutical composition may be about 100 μL to 1000 μL, or may be at least about 150 μL. The pharmaceutical composition may contain about 1,000 to about 1×10 9 Live RPE cells. The pharmaceutical composition may include about 333 live RPE cells / μL to about 2,000 live RPE cells / μL, about 444 live RPE cells / μL to about 1766 live RPE cells / μL, about 333 live RPE cells / μL, about 444 live RPE cells / μL, about 666 live RPE cells / μL, about 888 live RPE cells / μL, about 999 live RPE cells / μL or about 1,333 live RPE cells / μL.

[0082] In the pharmaceutical composition, the concentration of RPE cell can be high enough so that in 60 minutes, no more than about 30% of the RPE cells lose viability, and optionally in 4 hours, no more than about 10% of the RPE cells lose viability. The concentration of the RPE cell can be at least about 1,000 cells / μL, at least about 2,000 cells / μL, about 1,000-10,000 cells / μL, or about 2,000-5,000 cells / μL.

[0083] The pharmaceutical preparation may contain less than about 25%, 20%, 15%, 10%, 5%, 1%, 0.5%, 0.1%, 0.01%, 0.001%, or 0.0001% of cells that may not be RPE cells.

[0084] The average melanin content of the RPE cells can be less than 8pg / cell, less than 7pg / cell, less than 6pg / cell, less than 5pg / cell, less than 4pg / cell, less than 3pg / cell, cell, less than 2pg / cell and at least 0.1pg / cell and optionally at least 0.5pg / cell or 1pg / cell; 0.1-8pg / cell, 0.1-7pg / cell, 0.1-6pg / cell, 0.1-5pg / cell, 0.1-4pg / cell, 0.1-3pg / cell, 0.1-2pg / cell, 0.1-1pg / cell, 1-7pg / cell, 0.5-6pg / cell, or 1-5pg / cell.

[0085] At least 50%, at least 60%, at least 70%, or at least 80% of the cells in the pharmaceutical composition may be bestrophin+. At least 80%, at least 85%, at least 90%, at least 95%, or at least 99% of the cells in the pharmaceutical composition may be PAX6+ and / or MITF+. At least 80%, at least 85%, at least 90%, at least 95%, or at least 99% of the cells in the pharmaceutical composition may be PAX6+ and / or bestrophin+. At least 80%, at least 85%, at least 90%, at least 95%, or at least 99% of the cells in the pharmaceutical composition may be ZO-1+. At least 50%, at least 60%, or at least 70% of the cells in the pharmaceutical composition may be PAX6+ and bestrophin+. At least 90%, at least 95%, or at least 99% of the cells in the pharmaceutical composition may be PAX6+.

[0086] In exemplary embodiments, no more than about one cell per 1 million cells and optionally no more than two cells per 9 million cells in the pharmaceutical composition may be positive for both OCT-4 and alkaline phosphatase (AP) expression.

[0087] Needle or injection cannula can comprise at least a portion of the RPE cells. When loaded into the needle or injection cannula, the concentration of the RPE cells can be about 444 live cells / μL to about 1766 live cells / μL. The concentration of the live RPE cells delivered from the needle or injection cannula can be about 333 live cells / μL to about 1,333 live cells / μL. The diameter of the needle or injection cannula can be about 0.3mm to about 0.9. The diameter of the needle or injection cannula can be about 0.5 to about 0.6mm. The needle or injection cannula can include a tip having a diameter of about 0.09mm to about 0.15mm. The cannula can be MEDONE Cannula 25 / 38 g (0.50 mm (25 g) x 28 mm cannula with a 0.12 mm (38 g) x 5 mm tip) or Synergetics Angled 39 g Injection Cannula.

[0088] The RPE cells may include RPE cells that have been cryopreserved and thawed.

[0089] The RPE cells may be human.

[0090] The RPE cells such as human RPE cells can be produced from any source including pluripotent cells such as embryonic stem cells or induced pluripotent stem cells and donor adults or fetal tissues. The pluripotent stem cells can be positive for the expression of one or more markers, and the markers can include OCT-4, alkaline phosphatase, Sox2, TDGF-1, SSEA-3, SSEA-4, TRA-1-60 and / or TRA-1-81. The pluripotent cells can be human pluripotent cells, which can be cultivated in multilayer groups or embryoid bodies to be enough to make pigment epithelial cells appear in the culture. The time that is enough to make pigment epithelial cells appear in the culture can include at least about 1 week, at least about 2 weeks, at least about 3 weeks, at least about 4 weeks, at least about 5 weeks, at least about 6 weeks, or at least about 7 weeks, at least about 8 weeks. The multilayer groups or embryoid bodies can be cultivated in the culture medium that can include DMEM. The culture medium can include EB-DM, is basically composed of it, or is composed of it. The pigment epithelial cells can be separated and cultivated, thereby producing RPE cell groups. The separation may include enzymolysis, chemical or physical dissociation of cells or cell mass from culture, and pigment epithelial cells or cell mass are selected to include pigment epithelial cells. The embryoid body may be suspended culture and / or as adherent culture (e.g., suspended culture, then adherent culture). The embryoid body cultivated as adherent culture may produce one or more projections (outgrowth) comprising pigment epithelial cells. The pluripotent stem cell has the HLA antigen complexity of reduction. Before RPE is formed, the pluripotent cell culture may be selected from laminin, fibronectin, vitronectin, proteoglycan, nestin, collagen, collagen I, collagen IV, collagen VIII, heparan sulfate, Matrigel (TM) (soluble preparation from Engelbreth-Holm-Swarm (EHS) mouse sarcoma cells), CellStart, human basement membrane extract and any combination thereof on the matrix. The matrix may include Matrigel (TM) (soluble preparation from Engelbreth-Holm-Swarm (EHS) mouse sarcoma cells).

[0091] The pharmaceutical composition may comprise cells lacking substantial expression of one or more embryonic stem cell markers. The one or more embryonic stem cell markers may comprise OCT-4, NANOG, Rex-1, alkaline phosphatase, Sox2, TDGF-1, SSEA-3, SSEA-4, TRA-1-60 and / or TRA-1-81.

[0092] The RPE cells may be positive for the expression of one or more RPE cell markers. The one or more RPE cell markers may include RPE65, CRALBP, PEDF, yolk-like maculopathy protein, MITF, Otx2, PAX2, PAX6, ZO-1 and / or tyrosinase.

[0093] Described RPE cell can be produced by the following method, and described method comprises that RPE cell is maintained as resting cell the time that is enough to obtain described average melanin content.Described RPE cell can be produced by the following method, and described method comprises that RPE cell is maintained as resting cell the time that is enough to produce yolk-like maculopathy protein expression in at least 50% described RPE cell.

[0094] The pharmaceutical composition may be substantially free of mouse embryonic feeder cells (MEF) and human embryonic stem cells (hES).

[0095] The RPE cells may meet at least one of the standards listed in Table 1 and / or be manufactured according to good manufacturing practices (GMP).

[0096] The cryopreserved retinal pigment epithelial (RPE) cells or photoreceptor progenitor cells may be provided as a cryopreserved composition.

[0097] The RPE cells can exhibit a phagocytosis of photoreceptor outer segments (POS) that is at least 50% higher than an equal number of RPE cells from isolated adult eyes, or a phagocytosis of POS that is at least 75%, 100%, 150% or 200% higher than an equal number of RPE cells from isolated adult eyes; or a phagocytosis of photoreceptor outer segments (POS) that is at least 20% of the total concentration of POS after 24 hours, or a phagocytosis of photoreceptor outer segments (POS) that is at least 25%, 30%, 25%, 40% or 50% of the total concentration of POS after 24 hours. The photoreceptor progenitor cells may exhibit a phagocytosis rate of at least 50% higher than that of an equal number of photoreceptor progenitor cells, or a phagocytosis rate of at least 75%, 100%, 150% or 200% higher than that of an equal number of photoreceptor progenitor cells; or a phagocytosis rate of at least 20% of the total concentration of POS after 24 hours, or a phagocytosis rate of at least 25%, 30%, 25%, 40% or 50% of the total concentration of POS after 24 hours. The phagocytosis rate and degree of phagocytosis may depend on the culture time and maturity of the cells. Depending on the maturity and pigmentation of the cells, the binding rate and internalization rate of POS may be different. Based on the maturity of the cell culture, the percentage of cells capable of phagocytosis may be different.

[0098] By labeling the photoreceptor outer segments with dyes that are non-fluorescent or weakly fluorescent at neutral pH but become more fluorescent when acidified, it is possible to more sensitively measure POS internalized by RPE cells or photoreceptor progenitor cells in phagocytosis assays. Most quantitative methods for phagocytosis assessment (FACS, fluorescence microplate reader) do not distinguish between internalized and surface-bound fluorescent particles. In addition, FITC fluorescence is sensitive to pH, and FITC fluorescence is significantly reduced when pH is lower than 6, while the pH of lysosomes and phagosomes fused with lysosomes is lower than 5. Therefore, in some cases, the fluorescence of FITC-labeled OS does not represent the amount of actual internalized OS. According to its manufacturer (Life Technologies, Molecular Probes), pH-sensitive rhodamine-based The Red dye is non-fluorescent at neutral pH and turns bright red upon acidification. The dye is both fluorescent and pH sensitive and can therefore be used as a specific sensor for phagocytic events, whereby acidification of the phagosome following engulfment is indicated by red fluorescence.

[0099] Use dyes that are non-fluorescent or weakly fluorescent at neutral pH but become more fluorescent upon acidification (e.g. Red and CypHer5E, a LysoSensor dye from Life Technologies that fluoresces most strongly in acidic environments) to label the photoreceptor outer segments is a significant improvement over prior art methods and reagents. We used this pH-sensitive rhodamine-based Red dye was used to label bovine OS to specifically measure internalized particles.

[0100] When comparing FITC-labeled photoreceptor outer segments, -BioParticles and -labeled photoreceptor outer segments, all showed a significant increase in fluorescence in the phagocytosis assay at 37°C compared to 4°C ( Figure 1A -C). However, quantitative analysis showed that only about half of the RPE cell population at 37°C exhibited an increase in fluorescence relative to the 4°C control in the phagocytosis assay when incubated with FITC-labeled particles ( Figure 1A), and in 4 ℃ of controls, about half of the RPE cell groups also show that fluorescence increases significantly, which may indicate that there are particles of combination but non-internalization on the cell surface. Such particles on the cell surface can represent specific and non-specific binding. In addition, the explanation of the photoreceptor outer segment FACS data of FITC labeling is not very accurate, because some FITC fluorescence may be lost at low pH (Fig. 2), so once the particles are internalized and the phagosome is fused with the lysosome, then under the final low pH (4.5-5.5), some FITC fluorescence disappears. Therefore, the measured fluorescence includes some signals from the internalized particles and the loss of the additional signal from the non-specific binding particles on the surface. Labeled BioParticles and Neither of the labeled photoreceptor outer segments showed any fluorescence increase at 4°C ( Figure 1B and 1C ), but showed an increase at 37°C, thus allowing specific measurement of only internalized particles that fused with lysosomes.

[0101] As stated in this article, -labeled ROS become fluorescent at low pH, so the observed fluorescence shift indicates internalized particles. ROS labeled with FITC or other pH-insensitive dyes tend to show particles nonspecifically bound to the cell surface, POS specifically bound but not internalized, and / or POS internalized but not fused with lysosomes. Or other pH-sensitive dyes to replace the conventionally used FITC-labeled photoreceptor outer segments whose fluorescence is negatively correlated with acidity, or use Labeling of POS with other pH-sensitive and / or insensitive dyes improves the accuracy of phagocytosis assays because it allows measurement of phagocytosis of physiologically relevant targets and allows detailed interrogation of phagocytosis mechanisms.

[0102] In some embodiments, POS is broken before use with cells of interest. POS can be broken using, for example, sonication or shearing or other methods in the art. It has been found that, in some cases, broken POS results in higher phagocytosis readings from cells. This may help distinguish positive activity from control activity.

[0103] The phagocytosis assay can be performed using a single cell cell suspension, or a monolayer of cells can be used for the phagocytosis assay. Therefore, cells can be provided as a cell suspension, or they can be provided as a monolayer, including a cultured monolayer. The latter embodiment is useful, particularly if the cells are normally grown as a monolayer, because it allows the phagocytic activity of the cells to be measured as such cells are usually present. The cells can be incubated as an adherent layer (e.g., a monolayer) with a labeled POS, and then can be enzymatically digested (e.g., trypsinized) to make them into a single cell population, which can then be analyzed using, for example, flow cytometry.

[0104] In some embodiments, the cells are incubated with POS at a temperature of 17°C or above, or 18°C ​​or above, 19°C or above, or 20°C or above. The upper limit of the temperature range can be equal to or lower than 42°C, equal to or lower than 41°C, equal to or lower than 40°C, equal to or lower than 39°C, equal to or lower than 38°C, or equal to or lower than 37°C. Test phagocytic activity can be measured at these temperatures. The cells can be provided as a monolayer, including a cultured monolayer.

[0105] In some embodiments, the test cell or test cell population is incubated with the POS at a temperature range of 17-40°C, or 20-40°C, or 25-40°C, or 30-40°C, or 35-40°C, or at a temperature of about 37°C. The negative control may correspond to cells incubated with the POS at a temperature range of about 4-16°C, 5-16°C, 6-16°C, 7-16°C, 8-16°C, 9-16°C, 10-16°C, 11-16°C, or 12-16°C. The negative control may correspond to cells incubated with the POS at a temperature range of about 4-15°C, 5-15°C, 6-15°C, 7-15°C, 8-15°C, 9-15°C, 10-15°C, 11-15°C, or 12-15°C. The cells may be provided as a monolayer, including a cultured monolayer.

[0106] In some cases, the cells have been previously cryopreserved and thawed and briefly cultured to generate a monolayer. Once the cells are in the form of a monolayer, the cells can be tested for phagocytic activity as described herein.

[0107] In some embodiments, cells can be exposed to unlabeled POS for a period of time and then to fluorescently labeled POS to measure phagocytosis of the latter POS. In this way, cells can already be primed prior to the introduction of labeled POS.

[0108] definition

[0109] In order that the invention described herein may be fully understood, the following detailed description is set forth. Various embodiments of the present invention are described in detail and can be further illustrated by the examples provided.

[0110] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as those of ordinary skill in the art to which the present invention belongs. Although methods and materials similar or comparable to the methods and materials described herein can be used for the present invention or the test of the present invention, suitable methods and materials are described below. Materials, methods and examples are illustrative only, not restrictive. The following terms and definitions are provided herein.

[0111] As used in the description herein and in the appended claims, the meanings of “a,” “an,” and “the” include plural references unless the context clearly dictates otherwise. Also, as used in the description herein, the meaning of “in” includes “in” and “on” unless the context clearly dictates otherwise.

[0112] Throughout this document, the word "comprise" or variations such as "comprises" or "comprising", will be understood to imply the inclusion of a stated integer or group of integers but not the exclusion of any other integer or group of integers.

[0113] As used herein, "embryonic stem cell" (ES cell) refers broadly to cells derived from the inner cell mass of the blastocyst or morula that has been serially passed down as a cell line. ES cells can be derived from the fertilization of an egg cell with a sperm or DNA, nuclear transfer, parthenogenesis, or by the method of producing ES cells of homozygosity in the HLA region. ES cells can also refer to cells of mammalian embryos in the zygote, blastomere or blastocyst stage derived from fusion sperm and egg cell production, nuclear transfer, parthenogenesis or chromatin reprogramming, and then the reprogrammed chromatin is incorporated into the plasma membrane to produce cells. Embryonic stem cells (regardless of their source or the specific method for producing them) can be identified based on the following: (i) the ability to differentiate into cells of all three germ layers, (ii) at least expressing Oct-4 and alkaline phosphatase, and (iii) the ability to produce teratomas when transplanted into immunocompromised animals. The term also includes cells separated from one or more blastomeres of an embryo, preferably without destroying the rest of the embryo (see, e.g., Chung et al., Cell Stem Cell. 2008 Feb 7; 2(2): 113-7; U.S. Patent Publication No. (USP GPub No.) 20060206953; U.S. Patent Publication No. 2008 / 0057041, each of which is incorporated herein by reference in its entirety). The term also includes cells produced by somatic cell nuclear transfer, even if non-embryonic cells are used in the process. ES cells can be derived from fertilization of an egg cell with sperm or DNA, nuclear transplantation, parthenogenesis, or by methods of producing ES cells homozygous in the HLA region. ES cells can also be cells of mammalian embryos at the zygote, blastomere or blastocyst stage derived from fusion of sperm and egg cells, nuclear transfer, parthenogenesis or chromatin reprogramming, followed by incorporation of the reprogrammed chromatin into the plasma membrane to produce cells. The human embryonic stem cells of the present disclosure may include, but are not limited to, MA01, MA09, ACT-4, No.3, H1, H7, H9, H14 and ACT30 embryonic stem cells. In certain embodiments, the human ES cells used to generate RPE cells are derived and maintained according to GMP standards.

[0114] As used herein, "macular degeneration" refers broadly to diseases characterized by progressive loss of central vision associated with abnormalities of Bruch's membrane, neural retina, and retinal pigment epithelium. Macular degenerative diseases include, but are not limited to, age-related macular degeneration, North Carolina macular dystrophy, Sorsby's fundus dystrophy, fundus maculopathy, pattern dystrophy, Best's disease, macular lesions (malattia leventinese), Doyne's cellular choroiditis, dominant drusen, and radial drusen.

[0115] As used herein, "pluripotent stem cells" broadly refer to cells that are capable of prolonged or virtually indefinite proliferation in vitro while maintaining their undifferentiated state, exhibit a stable (preferably normal) karyotype, and have the ability to differentiate into all three germ layers (i.e., ectoderm, mesoderm, and endoderm) under appropriate conditions.

[0116] As used herein, "RPE cell", "differentiation of RPE cells", "ES-derived RPE cells" can be used interchangeably throughout the text to refer to RPE cells differentiated from pluripotent stem cells, such as using methods disclosed herein. The term is generally used to refer to the RPE cells differentiated, regardless of the degree of maturity of the cell, and therefore can encompass RPE cells of different maturity levels. RPE cells can be visually identified by their cobblestone morphology and the initial appearance of pigment. RPE cells can also be based on embryonic stem cell markers such as Oct-4 and NANOG based on the basic lack of expression and based on the expression of RPE markers such as RPE 65, PEDF, CRALBP and yolk-shaped maculopathy protein and molecular identification. For example, if expected staining pattern is observed, such as PAX6 positioned in the nucleus, yolk-shaped maculopathy protein (yolk-shaped maculopathy protein staining located at the clear line of the cell periphery) positioned in the plasma membrane with a polygonal pattern, outline the cell tight junction with a polygonal pattern and there is ZO-1 staining, the MITF staining detection limited to the nucleus, then cells are counted as positive for a given marker. Unless otherwise specified, RPE cells used herein refer to RPE cells differentiated in vitro from pluripotent stem cells.

[0117] As used herein, " mature RPE cells " and " mature differentiated RPE cells " can be used interchangeably in the full text, to refer broadly to the changes that occur after the initial differentiation RPE cells. Specifically, although RPE cells can be identified based on the initial appearance of pigment in part, mature RPE cells can be identified based on enhanced pigmentation after differentiation.

[0118] As used herein, " pigmentation " refers broadly to the pigmentation of any level, for example, the pigmentation that initially occurs when RPE cells are differentiated from ES cells.Pigmentation can change with the cell density and maturity of the RPE cells differentiated.The pigmentation of RPE cells can be identical with the average RPE cells after the terminal differentiation of RPE cells.The pigmentation of RPE cells may be more intense than the pigmentation of the average RPE cells after the terminal differentiation of RPE cells.After terminal differentiation, the pigmentation of RPE cells may be less than the pigmentation of average RPE cells.

[0119] "Photoreceptor progenitor cells" refer to cells of the neural retina that can be differentiated from embryonic stem cells or induced pluripotent stem cells and express the marker PAX6 but do not express the marker CHX10 (i.e., CHX10(-)). These cells transiently express CHX10 at the retinal neural progenitor stage, but CHX10 expression is turned off when the cells differentiate into the photoreceptor progenitor stage. Other markers expressed by photoreceptor progenitor cells may include: Pax6, Nr2e3, Trβ2, Mash1, RORβ, and NRL. Moreover, "photoreceptor cells" may refer to postmitotic cells that are differentiated from embryonic stem cells or induced pluripotent stem cells and express the cell marker rhodopsin or any of the three cone opsins, and optionally express rod or cone cGMP phosphodiesterase. Photoreceptor cells may also express the marker restore protein found in photoreceptor cells. Photoreceptor cells may be rod cells and / or cone cells.

[0120] Cell markers: Exemplary cell markers whose expression can be assessed include the following: PAX6, RX1, SIX3, SIX6, LHX2, TBX3, SOX2, CHX10, neuroepithelial stem cell protein, TRβ2, NR2E3, NRL, MASH1, RORβ, recoverin, opsin, rhodopsin, rod and cone cGMP phosphodiesterase, which can be assessed at the protein and / or mRNA level (see Fischer AJ, Reh TA, Dev Neurosci. 2001; 23(4-5):268-76; Baumer et al., Development. 2003 Jul; 130(13):2903-15, Swaroop et al., Nat Rev Neurosci. 2010 Aug; 11(8):563-76, Agathocleous and Harris, Annu. Rev. Cell. 2010 ... Dev.Biol.2009.25:45–69, the entire contents of which are incorporated herein by reference). The marker identifiers are generally used as in the literature and in the art, particularly in areas related to the context in which those gene identifiers are cited herein, which may include literature related to photoreceptors, rods, cones, photoreceptor differentiation, photoreceptor progenitors, neural differentiation, neural stem cells, pluripotent stem cells, and other areas as indicated by the context. In addition, the markers are generally human, for example, unless the context indicates otherwise. Conventional immunocytochemistry methods or conventional PCR methods well known to those of ordinary skill in the art can be used to identify cell markers.

[0121] As used herein, "signs" of disease refer broadly to any abnormality indicative of disease that is detectable upon examination of a patient; these are objective indicators of disease, in contrast to symptoms, which are subjective indicators of disease.

[0122] As used herein, "symptoms" of a disease broadly refer to any disease phenomena or deviations from normal structure, function, or sensation experienced by a patient and indicative of the disease.

[0123] As used herein, "therapy, therapeutic, treating, treat or treatment" refers broadly to treating a disease, preventing or reducing the development of a disease or its clinical symptoms, and / or alleviating a disease, causing the disease or its clinical symptoms to subside. Treatment includes preventing, preventing, treating, curing, remedying, reducing, alleviating and / or providing relief from a disease, signs and / or symptoms. Treatment includes alleviating signs and / or symptoms of a patient with persistent disease signs and / or symptoms (e.g., blindness, retinal deterioration). Treatment also includes "prevention" and "prevention." Prevention includes preventing the occurrence of a disease after treating a disease in a patient or reducing the incidence or severity of a disease in a patient. For the purpose of treatment, the term "reduction" refers broadly to a clinically significant reduction in signs and / or symptoms. Treatment includes treating recurrent or recurrent signs and / or symptoms (e.g., retinal degeneration, vision loss). Treatment includes, but is not limited to, excluding the appearance of signs and / or symptoms at any time and reducing existing signs and / or symptoms and eliminating existing signs and / or symptoms. Treatment includes treating chronic diseases ("maintenance") and acute diseases. For example, treating includes treating or preventing the recurrence or recurrence of signs and / or symptoms (eg, blindness, retinal degeneration).

[0124] The RPE of preparation or photoreceptor progenitor cell can have than equal number and be separated from the phagocytic rate of the POS of the RPE cell of adult (i.e. the adult at 25-80 years old, more preferably the adult at 50-80 years old) eye at least 50% higher, more preferably the phagocytic rate of at least 75%, 100%, 150% or even 200% photoreceptor cell outer segment (POS).The photoreceptor progenitor cell of this preparation can have than equal number and be separated from the phagocytic rate of the POS of the photoreceptor progenitor cell of adult (i.e. the adult at 25-80 years old, more preferably the adult at 50-80 years old) eye at least 50% higher, more preferably the phagocytic rate of at least 75%, 100%, 150% or even 200% photoreceptor cell outer segment (POS).

[0125] The RPE or photoreceptor progenitor cells of preparation can have at least 20% of the total concentration of POS after 24 hours, or the phagocytosis rate of the photoreceptor outer segment (POS) of at least 25%, 30%, 25%, 40% or 50% of the total concentration of POS after 24 hours. As an illustrative and non-restrictive example, the operating scheme described by Bergmann et al.FASEB Journal March 2004 vol. 18 pages 562-564 can be used to measure POS phagocytosis, and it has the change of non-FITC-labeled POS described herein.

[0126] The RPE or photoreceptor progenitor cell population may include differentiated RPE cells of varying maturity levels, or may be substantially pure for differentiated RPE cells of a particular maturity level. The RPE cells may be a substantially purified preparation comprising RPE cells of varying levels of maturity / pigmentation.

[0127] Cryopreservation preparation of RPE cells

[0128] RPE cell or photoreceptor progenitor cell can be stored by any suitable method known in the art (for example, cryogenic freezing) and can be frozen at any temperature suitable for storing cells.Before using these cells, they can be tested in mensuration of the present invention to determine the phagocytic activity and / or the effectiveness of cells.

[0129] RPE cells or photoreceptor progenitor cells that demonstrate efficacy in the phagocytosis assay of the present invention can be used to treat retinal degenerative diseases due to retinal detachment, retinal atypical hyperplasia, angioid streaks, myopic macular degeneration, or retinal atrophy or are associated with a variety of vision-altering disorders that lead to photoreceptor cell damage and blindness, such as choroideremia, diabetic retinopathy, macular degeneration (e.g., age-related macular degeneration), retinitis pigmentosa, and fundus maculopathy.

[0130] The RPE or photoreceptor progenitor cells provided herein can be human RPE or photoreceptor progenitor cells. However, please note that human cells can be used for human patients, as well as animal models or animal patients. For example, it can be tested in mice, rats, cats, dogs or non-human primate retinal degeneration models. In addition, human cells can be used therapeutically to treat animals in need, for example, for veterinary medicine.

[0131] Screening assay

[0132] The present disclosure provides methods for identifying agents that modulate the phagocytic activity of RPE cells or photoreceptor progenitor cells. Example

[0133] Having now generally described the invention, the invention will be more readily understood by reference to the following examples, which are included merely for the purpose of illustrating certain aspects and embodiments of the invention and are not intended to limit the invention.

[0134] RPE cells are derived from human embryonic stem cells (hESC) as previously described (Klimanskaya et al, 2004), and are used for passage 2 to 5 times after being separated from pigment cluster differentiation cultures. Cells are cultured in EGM-2 culture medium (Lonza) until confluence, and cells used in the experiment have produced differentiated RPE phenotypes after cells in RPE maintenance culture medium (Klimanskaya et al, 2004), the RPE phenotype characteristics of the differentiation are hexagonal morphology, different levels of brown pigment, cubic cell appearance, polarization and tight junction. Or, cells are used for experiment before they are fully mature but still after they converge.

[0135] Bovine Rod Outer Segments (Cat. No. 98740) were purchased from InVision Bioresources. FITC isomer (Cat. No. F1906) I was purchased from Life Technologies. Red Phagocytosis Particle Labeling Kit (Catalog No. A10026) was purchased from Life Technologies.

[0136] Labeling of POS with FITC

[0137] Resuspend a vial of 10 mg FITC isomer I to 2 mg / mL in 0.1 M sodium carbonate buffer (pH 9.5). Remove undiluted particles by centrifugation at 3000 g for 10 minutes, and use only the supernatant to label bovine ROS. Thaw 25 bovine eyeballs equivalent to the value of ROS and resuspend in 5 mL of wash buffer (10% sucrose in 20 mM phosphate buffer containing 5 mM taurine, pH 7.2). Add 1.5 mL of 2 mg / mL FITC supernatant to the resuspended ROS and let them incubate in the dark at room temperature with shaking for 1 hour. After incubation, centrifuge the ROS-FITC segments at 3000 g and resuspend in 10 mL of wash buffer. Repeat this washing step 2 times. After washing, resuspend in 2.5% sucrose in 10 mL DMEM (Gibco #11960) and centrifuge again at 3000 g for 10 minutes. Finally, resuspend the cells in 10 mL of 2.5% sucrose in DMEM, count the ROS-FITC particles using a hemocytometer, and adjust the concentration to 1 × 10 in 2.5% sucrose in DMEM. 8Particles / mL were prepared and the pellets were frozen at -80°C.

[0138] use Mark POS

[0139] Twenty-five bull eyes equivalent to the value of ROS were resuspended in Red Phagocytic Particle Labeling Kit in 4.165 mL of 0.1 M sodium bicarbonate buffer. Aliquot the ROS into 4750 μL aliquots in microcentrifuge tubes. Centrifuge the tubes at 10000 RPM for 1 minute and resuspend again in 750 μL of 0.1 M sodium bicarbonate buffer. The dye was resuspended in DMSO to a final concentration of 10 mM. Dye was added to ROS in sodium bicarbonate buffer to a final concentration of 0.5 mM and incubated in the dark for 45 minutes. After 45 minutes, 500 μL of "Component C" (from the kit) was added and centrifuged at 10,000 RPM for 1 minute. The supernatant was aspirated and resuspended in 1 mL of 100% methanol. The tube was vortexed for 30 seconds and centrifuged at 10,000 RPM for 1 minute. The methanol was aspirated and resuspended in 1 mL of "Component C" (wash buffer from the kit) and centrifuged again at 10,000 RPM for 1 minute. This wash step was repeated 2 times. All pellets were resuspended in a total of 20 mL of "Buffer B" (from the kit). ROS- 10 minutes, ROS- Resuspend in 2.5% sucrose in DMEM and adjust the concentration to 1 × 10 8 Particles / mL were prepared and the pellets were frozen at -80°C.

[0140] RPE cells and BioParticles conjugated with FITC or Labeled bovine outer segments were incubated at 37°C for different times ranging from 2 to 24 hours. Afterwards, the cells were washed, harvested by trypsin / dissociation buffer 1:1, centrifuged and analyzed by flow cytometry. As a negative control, cells were incubated at 4°C for the same time.

[0141] In addition, the interpretation of FITC-labeled ROS FACS data is not very accurate because some FITC fluorescence may be lost at low pH ( Figure 2A and B), so once the particles are internalized and the phagosomes fuse with the lysosomes, at the final low pH (4.5-5.5), some FITC fluorescence disappears. Therefore, the measured fluorescence includes some signal from the internalized particles and the loss of additional signal from non-specifically bound particles on the surface.

[0142] is a pH-sensitive fluorescent dye, and Neither the labeled BioParticles nor the ROS showed any fluorescence increase at 4°C ( Figure 1B and 1C ), thus allowing specific measurement of internalized particles that fuse with lysosomes.

[0143] use Labeling of ROS can improve the accuracy of phagocytosis assays and can replace or supplement FITC-labeled ROS to examine the complex mechanisms of phagocytosis in detail.

[0144] use E.coli fluorescent bioparticle labeling

[0145] By using Phagocytosis was assessed using a FACS-based assay using E. coli fluorescent bioparticles (Invitrogen). E.coli fluorescent bioparticles fluoresce when internalized in the reduced pH environment of intracellular phagosomes. Prepare bioparticles according to the manufacturer's instructions. The RPE that converges is incubated with a hole of 50-200 μL bioparticles / 4-well plate in a culture medium (Invitrogen) independent of CO2 at 37 ° C for 16-20 hours. The negative control plate is incubated at 4 ° C. Cells are examined under a microscope, harvested by trypsin and analyzed by counting 10,000 events on a C6 flow cytometer by FACS.

[0146] Table 1 RPE cell characterization and safety testing

[0147]

[0148]

[0149] RPE cells Phagocytosis of red labeled ROS.

[0150] hESC-derived RPE and ARPE-19 cells were cultured in RPE growth medium (RPE-GM) consisting of endothelial cell growth medium (Lonza, Cat. No. CC-3162, CC-3156).

[0151] For phagocytosis assay, RPE cells were plated at 5 × 10 5 cells / cm 2The density of 100 μg / ml was seeded in a 96-well culture plate (Becton-Dickinson) and maintained in a humid incubator at 37°C and 5% CO2. In order to obtain the best measurement reading, RPE cells were cultured in RPE-GM for 3-5 days and then the phagocytic ability was evaluated. If the cell culture time exceeds 5 days, RPE-GM is converted to RPE maintenance medium (RPE-MM) composed of DMEM supplemented with 10% fetal bovine serum, GlutaMax and Normocin. The culture medium is replaced every 2-3 days to provide sufficient nutrition. In order to measure the phagocytic activity of RPE cells, a pH-sensitive rhodamine-based Red labeled rod outer segments (ROS) (InVision Bioresources, catalog number 98740). ROS were labeled with the Red Microscale Labeling Kit (Thermo Fisher Scientific, catalog number P35363). Each well of confluent RPE cells was inoculated with 0.1 mL of DMEM medium containing 10% FBS and Normocin and 0.1 mL of labeled ROS reconstituted in DMEM supplemented with 10% FBS and Normocin. To evaluate the optimal phagocytic capacity of RPE cells, different ROS concentrations were tested: 1.5 × 10 6 , 3×10 6 , 3.75×10 6 , 5×10 6 , 6×10 6 , 7.5×10 6 , 10×10 6 and 13.5×10 6The hole of ROS / 96-well plate.In order to reduce ROS aggregation and increase phagocytosis efficiency, direct pulse ultrasonic treatment step is introduced during the reconstruction of rod cell outer segment.RPE cells and ROS are incubated for 20-28 hours at 37 ° C in an atmosphere of 5% CO2 and 95% air for test samples, and incubated for negative control at 12-15 ° C. The next day, after ROS and RPE cell monolayer were incubated for 20-28 hours, the culture medium was aspirated, and each well was washed 3 times with 0.2mL PBS (Gibco / Invitrogen#14190-250) without Ca / Mg. 0.2mL of 0.25% trypsin / EDTA (Sigma, catalog number T4049) was added to each well with a ratio of 1: 1, plus cell dissociation buffer (Gibco / Invitrogen, catalog number 13151), and incubated at room temperature until single cell suspension is visible (10-20 minutes). The cell suspension of each sample was transferred to an appropriately labeled round-bottom polystyrene tube containing 2 mL of DMEM plus 10% FBS to neutralize the reaction and centrifuged at 160 g for 5 minutes. The supernatant was decanted leaving approximately 0.2-0.25 mL of liquid. The sample tube was vortexed and ROS uptake by RPE cells was assessed using a BD Accuri C6 flow cytometer as previously described.

[0152] In order to further increase the phagocytic ability, the above steps can be followed. Prior to phagocytosis of ROS labeled with ROS Red, the naive RPE cell monolayer was rendered "competent" by exposure to unlabeled ROS for a defined period of time, with or without a recovery step.

[0153] References

[0154] Schwartz SD, Hubschman JP, Heilwell G, Franco-Cardenas V, Pan CK, Ostrick RM, Mickunas E, Gay R, Klimanskaya I, Lanza R. Embryonic stem cell trials formacular degeneration: a preliminary report.Lancet.2012Feb 25;379(9817):713-20.doi:10.1016 / S0140-6736(12)60028-2.Epub 2012Jan 24.PubMed PMID:22281388.

[0155] Klimanskaya I.Retinal pigment epithelium.Methods Enzymol.2006;418:169-94.PubMed PMID:17141036.

[0156] Lund RD,Wang S,Klimanskaya I,Holmes T,Ramos-Kelsey R,Lu B,Girman S,Bischoff N,SauvéY,Lanza R.Human embryonic stem cell-derived cells rescuevisual function in dystrophic RCS rats.Cloning Stem Cells.2006Fall;8(3):189-99.PubMed PMID:17009895.

[0157] Klimanskaya I,Hipp J,Rezai KA,West M,Atala A,Lanza R.Derivationandcomparative assessment of retinal pigment epithelium from human embryonicstem cells using transcriptomics.Cloning Stem Cells.2004;6(3):217-45.PubMedPMID:15671670.

[0158] Mao Y,Finnemann SC.Analysis of photoreceptor outer segmentphagocytosis by RPE cells in culture.Methods Mol Biol.2013;935:285-95.doi:10.1007 / 978-1-62703-080-9_20.PubMed PMID:23150376;PubMed Central PMCID:PMC3590840.

[0159] Finnemann SC,Bonilha VL,Marmorstein AD,Rodriguez-BoulanE.Phagocytosis of rod outer segments by retinal pigment epithelial cellsrequires alpha(v)beta5integrin for binding but not for internalization.ProcNatl Acad Sci U S A.1997Nov 25;94(24):12932-7.PubMed PMID:9371778;PubMedCentral PMCID:PMC24241.

[0160] Miksa M,Komura H,Wu R,Shah KG,Wang P.A novel method to determine theengulfment of apoptotic cells by macrophages using pHrodo succinimidylester.J Immunol Methods.2009 Mar 15;342(1-2):71-7.doi:10.1016 / j.jim.2008.11.019.Epub 2009 Jan 9.PubMed PMID:19135446;PubMed Central PMCID:PMC2675277.

[0161] Lu B,Malcuit C,Wang S,et al.Long-term safety and function of RPE fromhuman embryonic stem cells in preclinical models of macular degeneration.StemCells 2009;21,2125-2135.

[0162] Sparrow JR,Hicks D,Hamel CP.The retinal pigment epithelium in healthand disease.Curr Mol Med 2010;10,802-823.

[0163] Strauss O.The retinal pigment epithelium in visual function.PhysiolRev 2005;85,845-881.

Claims

1. A method for measuring phagocytic activity, comprising: (1) measuring the test fluorescence in a first aliquot of the cell population incubated with photoreceptor outer segments (POS) labeled with pHrodo® Red dye at a temperature ranging from room temperature to physiological temperature or from room temperature to 40°C, and (2) measuring control fluorescence in a second aliquot of the cell population incubated with POS labeled with pHrodo® Red dye at a temperature range of 10-16°C or 12-15°C, Wherein a test fluorescence that is stronger than the control fluorescence indicates phagocytic activity of the cell population.

2. A method for measuring phagocytic activity comprising: (1) measuring the test fluorescence in a first aliquot of the cell population incubated with pHrodo® Red labeled photoreceptor outer segments (POS) alone or with pHrodo® Red E. coli BioParticles at a temperature range from room temperature to physiological temperature or from room temperature to 40°C, and (2) measuring control fluorescence in a second aliquot of the cell population incubated with pHrodo® Red labeled photoreceptor outer segments (POS) alone or with pHrodo® Red E.coli BioParticles at a temperature range of 10-16°C or 12-15°C, Wherein a test fluorescence that is stronger than the control fluorescence indicates phagocytic activity of the cell population.

3. A method for determining whether a cell population is suitable for preparing a drug for treating a retinal degenerative disease, comprising: a) performing a phagocytosis assay involving a cell population and pHrodo® Red labeled photoreceptor outer segments (POS) and / or pHrodo® Red labeled BioParticles; and b) Analyze the phagocytosis rate of pHrodo® Red labeled POS and / or pHrodo® Red labeled BioParticles by cell populations, Among them: (i) the phagocytosis rate of pHrodo® Red labeled POS and / or pHrodo® Red labeled BioParticles by the cell population is at least 50% greater than the phagocytosis rate of pHrodo® Red labeled POS and / or pHrodo® Red labeled BioParticles by an equal number of RPE or photoreceptor progenitor cells derived from the adult eye, The cell population is suitable for treating retinal degenerative diseases. The cell population is a retinal pigment epithelial (RPE) cell population or a photoreceptor progenitor cell population generated by in vitro differentiation of pluripotent stem cells. The phagocytosis assay includes the following steps: incubating the cell population with pHrodo® Red labeled POS and / or pHrodo® Red labeled BioParticles for a time and at a temperature sufficient to allow cells in the cell population to phagocytize the pHrodo® Red labeled POS and / or pHrodo® Red labeled BioParticles, wherein the pHrodo® Red labeled POS and / or pHrodo® Red labeled BioParticles are labeled with a fluorescent marker that fluoresces more strongly at an acidic pH than at a higher pH, and Detect the fluorescence intensity of the cell population after incubation. The increase in fluorescence intensity compared to the control indicates that the cell population has phagocytosed the pHrodo® Red-labeled POS and / or pHrodo® Red-labeled BioParticles. wherein the cell population is incubated with pHrodo® Red labeled POS and / or pHrodo® Red labeled BioParticles at a temperature ranging from room temperature to physiological temperature or from room temperature to 40°C, and The controls were cells incubated with pHrodo® Red labeled POS and / or pHrodo® Red labeled BioParticles at a temperature range of 10-16°C or 12-15°C.

4. The method of claim 3, wherein the cell population is incubated with pHrodo® Red labeled POS and / or pHrodo® Red labeled BioParticles at a temperature range of 25-40°C or 34-40°C or at 37°C.

5. The method of claim 3 or claim 4, wherein the phagocytosis rate of the cell population to pHrodo® Red-labeled POS and / or pHrodo® Red-labeled BioParticles is at least 75% higher than the phagocytosis rate of an equal number of RPE or photoreceptor progenitor cells derived from an adult eye to pHrodo® Red-labeled POS and / or pHrodo® Red-labeled BioParticles.

6. The method of claim 3 or 4, wherein the phagocytosis rate of the cell population to pHrodo® Red-labeled POS and / or pHrodo® Red-labeled BioParticles is at least 100% higher than the phagocytosis rate of an equal number of RPE or photoreceptor progenitor cells derived from an adult eye to pHrodo® Red-labeled POS and / or pHrodo® Red-labeled BioParticles.

7. The method of claim 3 or 4, wherein the phagocytosis rate of the cell population to pHrodo® Red-labeled POS and / or pHrodo® Red-labeled BioParticles is at least 150% higher than the phagocytosis rate of an equal number of RPE or photoreceptor progenitor cells derived from an adult eye to pHrodo® Red-labeled POS and / or pHrodo® Red-labeled BioParticles.

8. The method of claim 3 or 4, wherein the phagocytosis rate of the cell population to pHrodo® Red-labeled POS and / or pHrodo® Red-labeled BioParticles is at least 200% higher than the phagocytosis rate of an equal number of RPE or photoreceptor progenitor cells derived from an adult eye to pHrodo® Red-labeled POS and / or pHrodo® Red-labeled BioParticles.

9. A method for determining whether a cell population is suitable for preparing a drug for treating a retinal degenerative disease, comprising: a) performing a phagocytosis assay involving a cell population and pHrodo® Red labeled photoreceptor outer segments (POS) and / or pHrodo® Red labeled BioParticles; and b) Analyze the phagocytosis rate of pHrodo® Red labeled POS and / or pHrodo® Red labeled BioParticles by cell populations, in when: (ii) the phagocytosis rate of pHrodo® Red labeled POS and / or pHrodo® Red labeled BioParticles by the cell population after 24 hours is at least 20% of the total concentration of pHrodo® Red labeled POS and / or pHrodo® Red labeled BioParticles, The cell population is suitable for treating retinal degenerative diseases. The cell population is a retinal pigment epithelial (RPE) cell population or a photoreceptor progenitor cell population generated by in vitro differentiation of pluripotent stem cells. The phagocytosis assay includes the following steps: incubating the cell population with pHrodo® Red labeled POS and / or pHrodo® Red labeled BioParticles for a time and at a temperature sufficient to allow cells in the cell population to phagocytize the pHrodo® Red labeled POS and / or pHrodo® Red labeled BioParticles, wherein the pHrodo® Red labeled POS and / or pHrodo® Red labeled BioParticles are labeled with a fluorescent marker that fluoresces more strongly at an acidic pH than at a higher pH, and Detect the fluorescence intensity of the cell population after incubation. The increase in fluorescence intensity compared to the control indicates that the cell population has phagocytosed the pHrodo® Red-labeled POS and / or pHrodo® Red-labeled BioParticles. wherein the cell population is incubated with pHrodo® Red labeled POS and / or pHrodo® Red labeled BioParticles at a temperature ranging from room temperature to physiological temperature or from room temperature to 40°C, and The controls were cells incubated with pHrodo® Red labeled POS and / or pHrodo® Red labeled BioParticles at a temperature range of 10-16°C or 12-15°C.

10. The method of claim 9, wherein the cell population is incubated with pHrodo® Red labeled POS and / or pHrodo® Red labeled BioParticles at a temperature range of 25-40°C or 34-40°C or at 37°C.

11. The method of claim 9 or 10, wherein the cell population is suitable for treating retinal degenerative diseases when the phagocytosis rate of pHrodo® Red labeled POS and / or pHrodo® Red labeled BioParticles by the cell population after 24 hours is at least 25% of the total concentration of pHrodo® Red labeled POS and / or pHrodo® Red labeled BioParticles.

12. The method of claim 9 or 10, wherein the cell population is suitable for treating retinal degenerative diseases when the phagocytosis rate of pHrodo® Red labeled POS and / or pHrodo® Red labeled BioParticles by the cell population after 24 hours is at least 30% of the total concentration of pHrodo® Red labeled POS and / or pHrodo® Red labeled BioParticles.

13. The method of claim 9 or 10, wherein the cell population is suitable for treating retinal degenerative diseases when the phagocytosis rate of pHrodo® Red labeled POS and / or pHrodo® Red labeled BioParticles by the cell population after 24 hours is at least 40% of the total concentration of pHrodo® Red labeled POS and / or pHrodo® Red labeled BioParticles.

14. The method of claim 9 or 10, wherein the cell population is suitable for treating retinal degenerative diseases when the phagocytosis rate of pHrodo® Red labeled POS and / or pHrodo® Red labeled BioParticles by the cell population after 24 hours is at least 50% of the total concentration of pHrodo® Red labeled POS and / or pHrodo® Red labeled BioParticles.

15. The method of claim 3 or 9, wherein the pHrodo® Red labeled POS and / or pHrodo® Red labeled BioParticles are labeled with a fluorescent marker that, when internalized into a low pH compartment of a cell by phagocytosis, has an increased fluorescent signal relative to its fluorescent signal when the fluorescent marker is present extracellularly; and The method comprises detecting the fluorescence of a cell population relative to a control after incubation with pHrodo® Red labeled POS and / or pHrodo® Red labeled BioParticles, and thereby quantifying the phagocytic activity of the cell population.

16. The method of claim 3 or 9, wherein fluorescence is detected by flow cytometry or using a microplate reader.

17. The method of claim 3 or 9, wherein the cell population is incubated with pHrodo® Red labeled POS and / or pHrodo® Red labeled BioParticles at a temperature range of 34-40°C or at 37°C.

18. The method of claim 3 or 9, wherein the control is cells incubated with pHrodo® Red labeled POS and / or pHrodo® Red labeled BioParticles at a temperature range of 12-15°C.

19. The method of claim 3 or 9, wherein the cell population and the control are incubated with pHrodo® Red labeled POS and / or pHrodo® Red labeled BioParticles for 16-20 hours.

20. The method of claim 3 or 9, wherein the cell population lacks expression of one or more embryonic stem cell markers, wherein the one or more embryonic stem cell markers are selected from OCT-4, NANOG, Rex-1, alkaline phosphatase, Sox2, TDGF-1, SSEA-3, SSEA-4, TRA-1-60 and TRA-1-81.

21. claim 3 or 9 methods, wherein cell mass is a RPE cell mass, it expresses one or more RPE cell markers, and described one or more RPE cell markers are selected from RPE65, CRALBP, PEDF, yolk-shaped maculopathy protein, MITF, Otx2, PAX2, PAX6, ZO-1 and tyrosinase.

22. The method of claim 3 or 9, wherein the retinal degenerative disease is selected from the group consisting of retinal detachment, retinal dysplasia, angioid streaks, retinal atrophy, choroideremia, diabetic retinopathy, macular degeneration, retinitis pigmentosa, and fundus flavimaculatus.

23. The method of claim 22, wherein the macular degeneration is age-related macular degeneration or myopic macular degeneration.

24. The method of claim 3 or 9, wherein the pHrodo® Red labeled POS is disrupted POS or ultrasonicated POS.

25. The method of claim 3 or 9, wherein the pHrodo® Red labeled BioParticles are pHrodo ® Red labeled E. coli BioParticles.

26. The method of claim 3 or 9, wherein the RPE cell is a human RPE cell or wherein the photoreceptor progenitor cell is a human photoreceptor progenitor cell.

27. A method for determining whether a cell population is suitable for preparing a drug for treating a retinal degenerative disease, comprising: incubating the cell population with pHrodo® Red labeled photoreceptor cell outer segments (POS) and / or pHrodo® Red labeled BioParticles for a time and at a temperature sufficient to allow cells in the cell population to phagocytose the pHrodo® Red labeled POS and / or the pHrodo® Red labeled BioParticles, wherein the pHrodo® Red labeled POS and / or the pHrodo® Red labeled BioParticles are labeled with a fluorescent marker that fluoresces more strongly at an acidic pH than at a higher pH, and detecting the fluorescence intensity of the cell population after incubation, wherein an increase in fluorescence intensity compared to the control indicates that the cells have phagocytosed the pHrodo® Red-labeled POS and / or the pHrodo® Red-labeled BioParticles and also indicates that the cell population is suitable for treating retinal degenerative diseases, wherein the cell population is incubated with pHrodo® Red labeled POS and / or pHrodo® Red labeled BioParticles at a temperature range of 25-40°C or 34-40°C or at 37°C, and The controls were cells incubated with pHrodo® Red labeled POS and / or pHrodo® Red labeled BioParticles at a temperature range of 10-16°C or 12-15°C.

28. The method of any one of claims 3, 9 or 27, further comprising assessing the proliferation potency of the cell population.

29. The method of claim 28, wherein a proliferation potency that is greater than the proliferation potency of cells from an adult eye indicates that the cell population is suitable for transplantation.